Co-Administration of RISPERDAL ® with Certain Other Medications
Co-administration of carbamazepine and other enzyme inducers ( e. g. , phenytoin, rifampin, phenobarbital) with risperidone would be expected to cause decreases in the plasma concentrations of active moiety ( the sum of risperidone and 9-hydroxyrisperidone) , which could lead to decreased efficacy of risperidone treatment. The dose of risperidone needs to be titrated accordingly for patients receiving these enzyme inducers, especially during initiation or discontinuation of therapy with these inducers ( see CLINICAL PHARMACOLOGY and PRECAUTIONS) .
Fluoxetine and paroxetine have been shown to increase the plasma concentration of risperidone 2.5-2.8 fold and 3-9 fold respectively. Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone. Paroxetine lowered the concentration of 9-hydroxyrisperidone an average of 13% . The dose of risperidone needs to be titrated accordingly when fluoxetine or paroxetine is co-administered ( see CLINICAL PHARMACOLOGY and PRECAUTIONS) .
Directions for Use of RISPERDAL ® M-TAB Orally Disintegrating Tablets
RISPERDAL ® M-TAB Orally Disintegrating Tablets are supplied in blister packs of 4 tablet units each. .
Do not open the blister until ready to administer. For single tablet removal, separate one of the four blister units by tearing apart at the perforations. Bend the corner where indicated. Peel back foil to expose the tablet. DO NOT push the tablet through the foil because this could damage the tablet.
Using dry hands, remove the tablet from the blister unit and immediately place the entire RISPERDAL ® M-TAB Orally Disintegrating Tablet on the tongue. The RISPERDAL ® M-TAB Orally Disintegrating Tablet should be consumed immediately, as the tablet cannot be stored once removed from the blister unit. RISPERDAL ® M-TAB Orally Disintegrating Tablets disintegrate in the mouth within seconds and can be swallowed subsequently with or without liquid. Patients should not attempt to split or to chew the tablet.